ERBB2 and breast carcinoma: Some of the variables showed that NSM was beneficial for breast cancer patients compared with TM (Fig. 3), including age > 46, White race, median household income ≥ $70,000, ER positive,PR positive, HER2 negative, HR+/HER2- subtype, nonradiotherapy, and nonchemotherapy (P < 0.05).